Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the treatment of advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
DRUG: Anlotinib Hydrochloride, Paclitaxel, cisplatin
Progress free survival (PFS), From first treatment，each 42 or 63 days until PD or death(up to 24 months)
Objective Response Rate (ORR), each 42 or 63 days until intolerant the toxicity or PD (up to 24 months) ]|Disease Control Rate (DCR), each 42 or 63 days until intolerant the toxicity or PD (up to 24 months) ]|Duration of Response(DOR), each 42 or 63 days until intolerant the toxicity or PD (up to 24 months)
To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the treatment of advanced esophageal squamous cell carcinoma.